KINDAI UNIVERSITY


※苗字と名前の間にスペースをあけ、入力してください

鶴谷 純司ツルタニ ジュンジ

プロフィール

所属部署名医学科 / 医学研究科
職名准教授
学位博士(医学)
専門肺がん、乳がんの診断、固形がんの薬物療法
ジャンル医療・健康/がん治療
コメンテータガイドhttp://www.kindai.ac.jp/meikan/781-tsurutani-junji.html
ホームページURL
メールアドレス
Last Updated :2017/11/21

コミュニケーション情報 byコメンテータガイド

コメント

    当科では、がん薬物療法専門医を目指した「がんプロフェッショナル養成プラン」という教育プログラムやがん分子標的治療の適正な治療法を確立するための基礎研究、臨床試験を実施しています。

報道関連出演・掲載一覧

    <報道関連出演・掲載一覧>

    ●2016/7/30
     朝日新聞
     乳がん治療薬について
    ●2016/6/10
     毎日放送「ちちんぷいぷい」
     乳がんについて

研究活動情報

研究分野

  • 腫瘍学, 腫瘍治療学, 腫瘍内科

研究キーワード

  • 肺癌, 乳癌, , 臨床試験, 腫瘍内科

論文

  • Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer., Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K., Biomed Rep, 7, 4, 380, 384,   2017年10月, 査読有り
  • Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid., Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S., J Bone Oncol, 31, 8, 18, 22,   2017年08月, 査読有り
  • Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine., Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K., Int J Behav Med.,   2017年08月, 査読有り
  • T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer., Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K., Mol Cancer Ther,   2017年08月, 査読有り
  • DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance., Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J., Int J Cancer.,   2017年07月, 査読有り
  • Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement., Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, Okuno K, Iwasa T, Tsurutani J, Nakagawa K, Masaaki O, Hiroaki N., Mol Clin Oncol,   2017年07月, 査読有り
  • Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015., Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y., Chemotherapy,   2017年06月, 査読有り
  • Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study., Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T., Invest New Drugs,   2017年06月, 査読有り
  • Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1., Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J., Oncotarget, 7, 51, 84860, 84871,   2016年12月, 査読有り
  • Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease., Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K., Invest New Drugs,   2016年06月, 査読有り
  • Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors., Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K., Invest New Drugs. ,   2016年06月, 査読有り
  • The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition., Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H., Breast Cancer,   2016年05月, 査読有り
  • Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report., Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Shimizu T, Tsurutani J, Nakagawa K., Anticancer Drugs,   2016年03月, 査読有り
  • Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial., Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y, Lancet Oncol,   2016年01月, 査読有り
  • HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer., Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K., Oncotarget,   2016年01月, 査読有り
  • Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer., Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K., Cancer Sci,   2015年06月, 査読有り
  • Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing., Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K., PLoS One,   2015年05月, 査読有り
  • Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors., Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K., Invest New Drugs,   2015年04月, 査読有り
  • A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer., Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K., Br J Cancer,   2015年03月, 査読有り
  • Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer., Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, Kaneda H, Kurata T, Tsurutani J, Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, Nakagawa K., J Thorac Oncol,   2015年02月, 査読有り
  • The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer., Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S, Breast Cancer,   2015年01月, 査読有り
  • Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer., Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K., Invest New Drugs,   2014年10月, 査読有り
  • Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status., Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H., Breast,   2014年08月, 査読有り
  • Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines., Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K., Springerplus,   2014年08月, 査読有り
  • Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer., Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Sakamoto J, Morita S, Taguchi T., Anticancer Res,   2014年07月, 査読有り
  • Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection., Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K., PLoS One,   2014年07月, 査読有り
  • Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer., Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA., Oncotarget,   2014年02月, 査読有り
  • Regression of brain metastases from breast cancer with eribulin: a case report., Matsuoka H, Tsurutani J, Tanizaki J, Iwasa T, Komoike Y, Koyama A, Nakagawa K., BMC Res Notes,   2013年12月, 査読有り
  • Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice., Saeki T, Tokuda Y, Takigawa N, Tsurutani J., Gan To Kagaku Ryoho,   2013年10月
  • A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer., Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K., Invest New Drugs,   2013年06月, 査読有り
  • Perspectives in drug development for cancer therapy in Asia., 中川和彦、鶴谷純司, Chin Clin Oncol,   2012年12月
  • Resistant mechanisms against breast cancer treatment and therapeutic strategies]., 谷崎潤子、鶴谷純司, 日本臨床,   2012年11月
  • Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients., Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K., Oncol Rep,   2012年05月, 査読有り
  • NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer., Azuma K, Kawahara A, Hattori S, Taira T, Tsurutani J, Watari K, Shibata T, Murakami Y, Takamori S, Ono M, Izumi H, Kage M, Yanagawa T, Nakagawa K, Hoshino T, Kuwano M., J Thorac Oncol,   2012年05月, 査読有り
  • Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin., Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, Fujisaka Y, Kaneda H, Tsurutani J, Nakagawa K., Anticancer Res,   2012年05月, 査読有り
  • Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC., 武田 真幸, 岡本 勇, 鶴谷 純司, 大磯 直毅, 川田 暁, 中川 和彦, Jpn J Clin Oncol 2012, 42, 6, 528, 533,   2012年06月, 査読有り
  • Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients., Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Yamanaka T, Tanaka K, Nishio K, Nakagawa K., Anticancer Res,   2011年12月, 査読有り
  • Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B., Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K., Breast Cancer,   2011年11月, 査読有り
  • Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance., Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC, Travis WD, Jen J, Dennis PA., PLoS One,   2011年08月, 査読有り
  • High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin., Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K., Int J Clin Oncol.,   2011年06月, 査読有り
  • Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure., Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K., Biochem Biophys Res Commun,   2011年04月, 査読有り
  • Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male., Hirao A, Oiso N, Tsurutani J, Kimura M, Watatani M, Nakagawa K, Kawada A., Case Rep Dermatol,   2011年02月, 査読有り
  • Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors., Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Ohki E, Kimura N, Hashimoto J, Nakagawa K., Invest New Drugs,   2010年10月, 査読有り
  • A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904), 倉田 宝保, 小宮 武文, 鶴谷 純司, 宮﨑 昌樹, 田村 研治, 中川 和彦, 福岡 正博, Koji Takeda, Nobuyuki Yamamoto, Japanese Journal of Clinical Oncology, 40, 10, 992, 994,   2010年06月, 査読有り
  • FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth., Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K., Cancer Res,   2010年02月, 査読有り
  • Does escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer., 岡本 勇, 宮﨑 昌樹, 米阪 仁雄, 清田 秀美, 鶴谷 純司, 上田 眞也, 市川靖子, 武田 真幸, 中川 和彦, Koji Takeda Haruko Daga, Risa Sekiguchi Kiyomi Tominaga Sotaro Enatsu Yoshihiro Nambu, Lung Cancer, 70, 2, 168, 173,   2010年
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial., Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, Lancet Oncol, 11, 2, 121, 128,   2009年12月, 査読有り
  • Zoledronic acid-induced regression of multiple metastases at nonskeletal sites., Okamoto K, Tsurutani J, Terashima M, Okamoto I, Nakagawa K., Ann Oncol,   2009年03月, 査読有り
  • Lemierre's syndrome followed by acute respiratory distress syndrome successfully rescued by antibiotics and hemoperfusion with polymyxin B-immobilized fiber., Takazono T, Izumikawa K, Tsurutani J, Tanaka A, Kakugawa T, Fukuda Y, Saito M, Kurihara S, Imamura Y, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Kohno S., Jpn J Infect Dis,   2009年03月, 査読有り
  • Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo., Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA., Clin Cancer Res,   2007年09月, 査読有り
  • Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors., Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA., Clin Cancer Res,   2007年04月, 査読有り
  • Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma., Tsurutani J, Steinberg SM, Ballas M, Robertson M, LoPiccolo J, Soda H, Kohno S, Egilsson V, Dennis PA., Lung Cancer.,   2006年11月, 査読有り
  • Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer., Kinoshita A, Fukuda M, Soda H, Nagashima S, Fukuda M, Takatani H, Kuba M, Nakamura Y, Tsurutani J, Kohno S, Oka M, Br J Cancer,   2006年05月, 査読有り
  • Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma., Tsurutani J, Ballas MS, Dennis PA., J Clin Oncol,   2006年04月
  • Gefitinib for refractory advanced non-small-cell lung cancer., Tsurutani J, Ballas M, Steinberg SM, Egilsson V, Dennis PA., Lancet,   2006年01月
  • Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer., Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M., Anticancer Res,   2006年01月, 査読有り
  • Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors., Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA., J Clin Oncol,   2005年12月, 査読有り
  • Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells., Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S., Lung Cancer,   2005年09月, 査読有り
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy., Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA., Cancer Res,   2005年09月, 査読有り
  • Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes., Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, Kirsch IR, Kaye FJ., Cancer Res,   2005年08月, 査読有り
  • Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells., Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA., Carcinogenesis,   2005年03月, 査読有り
  • Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance., Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S., Cancer Res,   2005年02月, 査読有り
  • Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer., Tsurutani J, Dennis PA., J Natl Cancer Inst,   2004年12月, 査読有り
  • Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E., Fiala ES, Sohn OS, Wang CX, Seibert E, Tsurutani J, Dennis PA, El-Bayoumy K, Sodum RS, Desai D, Reinhardt J, Aliaga C., Carcinogenesis,   2004年12月, 査読有り
  • The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells., Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S, Kohno S., Mol Cancer Ther,   2004年11月, 査読有り
  • Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer., Fukuda M, Oka M, Soda H, Kinoshita A, Fukuda M, Nagashima S, Kuba M, Takatani H, Tsurutani J, Nakamura Y, Kasai T, Inoue Y, Soejima Y, Kohno S;, Cancer Chemother Pharmacol,   2004年09月, 査読有り
  • Autoimmunity to heat shock protein 40 in ulcerative colitis., Sato S, Oka M, Noguchi Y, Soda H, Tsurutani J, Nakamura Y, Kitazaki T, Mizuta Y, Takeshima F, Murase K, Murata I, Ohtsuka K, Kohno S, J Int Med Res,   2004年05月, 査読有り
  • Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues., Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, Li M, Jung M, West KA, Gills JG, Kozikowski AP, Dennis PA., Cancer Res,   2004年04月, 査読有り
  • Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic., Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S., Int J Cancer.,   2004年01月, 査読有り
  • Expression and functional analyses of breast cancer resistance protein in lung cancer., Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S., Clin Cancer Res,   2003年08月, 査読有り
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors., Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL., Oncogene,   2003年05月, 査読有り
  • Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines., Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, Nakamura Y, Nakatomi K, Shiozawa K, Amada YY, Kamihira S, Kohno S., 長崎大学医学部, 104, 2, 238, 242,   2003年03月, 査読有り
  • Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer., Oka M, Fukuda M, Kuba M, Ichiki M, Rikimaru T, Soda H, Tsurutani J, Nakamura Y, Kawabata S, Nakatomi K, Narasaki F, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S., Eur J Cancer,   2002年10月, 査読有り
  • Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer., Kasai T, Oka M, Soda H, Tsurutani J, Fukuda M, Nakamura Y, Kawabata S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S., Eur J Cancer,   2002年09月, 査読有り
  • Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan., Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, Syunichi N, Tohda A, Fukuoka M, Nakagawa K., Lung Cancer,   2002年03月, 査読有り
  • Mutational analysis of the beta-tubulin gene in lung cancer., Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M, Kohno S, Fukuoka M, Nakagawa K., Lung Cancer,   2002年01月, 査読有り
  • Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer., Oka M, Fukuda M, Nagashima S, Fukuda M, Kinoshita A, Soda H, Doi S, Narasaki F, Suenaga M, Takatani H, Nakamura Y, Kawabata S, Tsurutani J, Kanda T, Kohno S., Cancer Chemother Pharmacol.,   2001年12月, 査読有り
  • A case of multidrug-resistant pulmonary tuberculosis., Tsurutani J, Sohda H, Oka M, Kohno S, Nihon Kokyuki Gakkai Zasshi,   2000年08月, 査読有り
  • Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers., Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S., Clin Cancer Res,   1999年12月, 査読有り
  • A case of pulmonary actinomycosis marked by diagnostic difficulty, Tsurutani J, Tominaga M, Furukawa T, Fukuda M, Soda H, Oka M, Kohno S., Nihon Kokyuki Gakkai Zasshi,   1999年11月
  • Bronchoscopic therapy for mucosa-associated lymphoid tissue lymphoma of the trachea., Tsurutani J, Kinoshita A, Kaida H, Fujii H, Narasaki F, Fukuda M, Oka M, Kohno S., Intern Med,   1999年03月
  • Bronchial artery aneurysm as a cause of atelectasis., Oka M, Fukuda M, Terashi K, Takatani H, Narasaki F, Nakano R, Tsurutani J, Nakamura Y, Kasai T, Nagashima S, Noguchi Y, Soda H, Kohno S., Intern Med,   1997年12月
  • Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy., Matsumoto Y, Oka M, Sakamoto A, Narasaki F, Fukuda M, Takatani H, Terashi K, Ikeda K, Tsurutani J, Nagashima S, Soda H, Kohno S., Anticancer Res,   1997年09月, 査読有り
  • P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers., Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, Ikeda K, Tsurutani J, Ikuno N, Omagari K, Mizuta Y, Soda H, Gudas JM, Kohno S., Jpn J Cancer Res,   1997年08月, 査読有り

講演・口頭発表等

  • Updated results of phase 1 study of DS-8201a in patinets with HER2 expressing non-breast, non-gastric malignancies, 鶴谷純司, ESMO,   2017年09月11日
  • 転移性乳癌, 鶴谷純司, Best of ASCO,   2017年06月
  • Personalized medicine in HER2 positive disease, 鶴谷純司, 日本臨床腫瘍学会学術集会,   2016年07月
  • Liquid Biopsy, 鶴谷純司, 日本臨床腫瘍学会学術集会,   2015年07月
  • 転移性乳癌, 鶴谷純司, Best of ASCO,   2015年06月
  • Randomized Phase III study of Taxane vs. S-1 in metastatic breast cancer , 鶴谷純司, 日本臨床腫瘍学会学術集会,   2014年07月
  • Phase II study of weekly paclitaxel for relapsed small cell lung cancer., 倉田 宝保, 鶴谷 純司, 田村 研治, 中川 和彦, 福岡 正博, Yamamoto N Tamura K Takada M Kudoh S Kawahara M , ASCO,   2002年, ASCO
  • 既治療無効小細胞肺癌に対するパクリタキセル毎週投与の第II相試験, 倉田 宝保, 鶴谷 純司, 田村 研治, 中川 和彦, 福岡 正博, 山本信之 梁尚志 高田実 工藤新三 河原正明, 日本内科学会総会,   2002年, 日本内科学会総会
  • A phase Ⅲ、first-line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR), 鶴谷 純司, 岡本 勇, 福岡正博, 中川 和彦, 他5名, 34th ESMO,   2009年09月, 34th ESMO
  • ゾレドロン酸単剤で多臓器転移巣に対して抗腫瘍効果を認めた原発不明がんの一例, 鶴谷 純司, 牧村ちひろ, 東 公一, 武田 真幸, 竹澤 健, 岡本 渉, 清田秀美, 林 秀敏, 田中 薫, 岡本邦男, 谷崎潤子, 岡本 勇, 西條長宏, 福岡正博, 中川 和彦, 第8回日本臨床腫瘍学会総会,   2010年03月, 第8回日本臨床腫瘍学会総会
  • 進行肺腺癌を対象としたゲフェチニブ/S-1 併用療法第1相臨床試験, 清田 秀美, 岡本 勇, 谷﨑 潤子, 文田 壮一, 岡本 邦男, 牧村 ちひろ, 竹澤 健, 田中 薫, 林 秀敏, 岡本 渉, 寺嶋応顕, 東 公一, 金田裕靖, 武田真幸, 上田 眞也, 米阪 仁雄, 藤阪 保仁, 鶴谷 純司, 宮﨑 昌樹, 佐藤 太郎, 倉田 宝保, 中川 和彦, 第92回日本肺癌学会関西支部会,   2010年07月, 第92回日本肺癌学会関西支部会
  • 進行肺腺癌を対象としたゲフィチニブ/S-1併用療法第1層臨床試験, 清田 秀美, 岡本 勇, 田中 薫, 林 秀敏, 寺嶋応顕, 東 公一, 武田真幸, 米阪 仁雄, 藤阪 保仁, 鶴谷 純司, 宮﨑 昌樹, 佐藤 太郎, 倉田 宝保, 中川 和彦, 他, 第51回日本肺癌学会総会,   2010年11月, 第51回日本肺癌学会総会
  • 近畿大学における乳癌に対する治療方針, 金森 修一, 西川 龍之, 立花 和泉, 中松 清志, 石川 一樹, 小池 竜太, 松浦 知弘, 西村 恭昌, 藤島 成, 安積 達也, 橋本 幸彦, 塩﨑 均, 鶴谷 純司, 京都放射線腫瘍研究会,   2012年03月, 京都放射線腫瘍研究会
    概要:近畿大学における乳癌に対する乳腺外科・腫瘍内科・放射線治療科の取り組みと最新の治療方針について報告した。
  • エリブリン療法における用量調節の重要性について, 鶴谷 純司, 牧村ちひろ, 松岡弘道, 中川 和彦, 第20回日本乳癌学会学術総会,   2012年06月, 第20回日本乳癌学会学術総会
  • 乳がん領域における近年の進歩, 鶴谷 純司, 第10回日本臨床腫瘍学会学術集会,   2012年07月, 第10回日本臨床腫瘍学会学術集会

受賞

  •   2016年04月, 日本癌治療学会, 研究助成, cfDNA analysis in HER2 positve breast cancer
  •   2015年10月, 近畿大学医学会, 研究奨励賞, Phase I study of nab-paclitaxel and S-1 in ABC
  •   2013年09月, Lynn Sage Cancer Symposium (Chicago), Travel Award

競争的資金

  • 文部科学省, 科学研究費助成事業, H E R 2 陽 性 乳 癌 、 胃 癌 に お け る h e r e g u l i n に よ る 抗 H E R 2 薬 の 効 果 予 測, 鶴谷純司